Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients

Next Previous
X
Search
Trial Profile

Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Ciclosporin (Primary) ; Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Mycophenolic acid (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms DTG-SOT

    • Most Recent Events

    • 04 Feb 2020 Planned End Date changed from 24 Jul 2019 to 1 Jan 2021.
    • 04 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jul 2020.
    • 04 Feb 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top